IN2013MN02442A - - Google Patents

Download PDF

Info

Publication number
IN2013MN02442A
IN2013MN02442A IN2442MUN2013A IN2013MN02442A IN 2013MN02442 A IN2013MN02442 A IN 2013MN02442A IN 2442MUN2013 A IN2442MUN2013 A IN 2442MUN2013A IN 2013MN02442 A IN2013MN02442 A IN 2013MN02442A
Authority
IN
India
Prior art keywords
polypeptide
fusion proteins
relates
molecules
methods
Prior art date
Application number
Inventor
John C Timmer
Brendan P Eckelman
Grant B Guenther
Peter L Nguy
Henry Chan
Quinn Deveraux
Original Assignee
Inhibrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Llc filed Critical Inhibrx Llc
Publication of IN2013MN02442A publication Critical patent/IN2013MN02442A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Abstract

This invention relates to fusion proteins that include a whey acidic protein (WAP) domain containing polypeptide and a second polypeptide. Additionally the invention relates to fusion proteins that include a WAP domain containing polypeptide a second polypeptide and a third polypeptide. The second and/or third polypeptides of the fusion proteins of the invention are an Fc polypeptide; an albumin polypeptide; a cytokine targeting polypeptide; or a serpin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications as well as methods of producing such molecules.
IN2442MUN2013 2011-06-28 2012-06-28 IN2013MN02442A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161502052P 2011-06-28 2011-06-28
US201161565625P 2011-12-01 2011-12-01
US201261638168P 2012-04-25 2012-04-25
US201261638516P 2012-04-26 2012-04-26
PCT/US2012/044742 WO2013003649A2 (en) 2011-06-28 2012-06-28 Wap domain fusion polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
IN2013MN02442A true IN2013MN02442A (en) 2015-06-12

Family

ID=47424808

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2442MUN2013 IN2013MN02442A (en) 2011-06-28 2012-06-28

Country Status (12)

Country Link
US (2) US8986688B2 (en)
EP (1) EP2726093A4 (en)
JP (1) JP2014528913A (en)
KR (1) KR20140068861A (en)
CN (1) CN103946388A (en)
AU (2) AU2012275295B2 (en)
BR (1) BR112013033801A2 (en)
CA (1) CA2839622A1 (en)
IN (1) IN2013MN02442A (en)
MX (1) MX356433B (en)
RU (1) RU2639526C2 (en)
WO (1) WO2013003649A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2723370A4 (en) 2011-06-24 2015-06-03 Univ Colorado Regents Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
IN2013MN02442A (en) 2011-06-28 2015-06-12 Inhibrx Llc
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
KR102231139B1 (en) 2011-06-28 2021-03-24 인히브릭스, 인크. Serpin fusion polypeptides and methods of use thereof
WO2013106589A1 (en) * 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US20160024179A1 (en) * 2013-03-15 2016-01-28 Pyranose Biotherapeutics, Inc. Modified fc fusion proteins
CN103804484B (en) * 2014-01-24 2016-03-16 南京必优康生物技术有限公司 A kind of net erythrocyte growth factor and its preparation method and application
ES2793051T3 (en) 2014-07-23 2020-11-12 Inova Diagnostics Inc Compositions and methods for the diagnosis of rheumatoid arthritis
IL308589A (en) * 2014-10-27 2024-01-01 Inhibrx Inc Serpin fusion polypeptides and methods of use thereof
MA41374A (en) * 2015-01-20 2017-11-28 Cytomx Therapeutics Inc MATRIX METALLOPROTEASE CLIVABLE AND SERINE PROTEASE CLIVABLE SUBSTRATES AND METHODS OF USE THEREOF
WO2017192580A1 (en) * 2016-05-02 2017-11-09 The Regents Of The University Of California Novel fusion proteins for treating inflammatory diseases
US10839195B2 (en) * 2017-08-08 2020-11-17 Uchicago Argonne, Llc Machine learning technique to identify grains in polycrystalline materials samples
US11663494B2 (en) 2019-12-05 2023-05-30 Uchicago Argonne, Llc Systems and methods for hierarchical multi-objective optimization
CN110964094B (en) * 2019-12-20 2021-11-02 华中科技大学 Human leukocyte protease inhibitor and its recombinant preparation and application
US11651839B2 (en) 2020-03-02 2023-05-16 Uchicago Argonne, Llc Systems and methods for generating phase diagrams for metastable material states
US11710038B2 (en) 2020-04-13 2023-07-25 Uchicago Argonne, Llc Systems and methods for active learning from sparse training data
MX2023004933A (en) * 2020-10-29 2023-06-06 Formycon Ag Ace2 fusion proteins and uses thereof.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2364471A1 (en) * 1999-03-01 2000-09-08 Human Genome Sciences, Inc. Human serpin proteins
AU2050501A (en) * 1999-12-01 2001-06-12 Human Genome Sciences, Inc. Four disulfide core domain-containing (fdcd) polynucleotides, polypeptides, and antibodies
FR2814957B1 (en) * 2000-10-06 2002-12-20 Aventis Pasteur VACCINE COMPOSITION AND STABILIZATION METHOD
CA2434237C (en) 2000-12-07 2012-05-15 Eli Lilly And Company Glp-1 fusion proteins
EP2354149B1 (en) * 2000-12-12 2017-08-30 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
DE10303664A1 (en) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Detection molecules for the treatment and detection of tumors
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
KR20050047030A (en) * 2003-11-13 2005-05-19 한미약품 주식회사 Igg fc fragment for a drug carrier and method for the preparation thereof
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
US7914771B2 (en) * 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
EP1781700B1 (en) 2004-08-03 2014-03-19 TransTech Pharma, LLC Rage fusion proteins and methods of use
US7399746B2 (en) * 2004-10-06 2008-07-15 Mcgill University Agents for wound healing
ES2707152T3 (en) * 2005-04-15 2019-04-02 Macrogenics Inc Covalent diabodies and uses thereof
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
WO2006129849A1 (en) 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. Anti-cd14 antibody-fused protein
EP2012819A2 (en) * 2006-03-30 2009-01-14 The Research Foundation Of the City university of New York Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2008077478A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
US8598315B2 (en) * 2007-10-02 2013-12-03 Research Foundation Of City University Of New York Protein transduction domains derived from secretory leukocyte protease inhibitor
AR064713A1 (en) * 2007-12-28 2009-04-22 Consejo Nac Invest Cient Tec FUSION PROTEIN THAT JOINS TRANSGLUTAMINASES, COMPOSITIONS THAT UNDERSTAND IT, MICRO-SPHERES THAT UNDERSTAND IT, USES AND METHODS
SE533763C2 (en) * 2009-05-04 2010-12-28 Lars Hammar Suspension device
GB201003559D0 (en) 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
US10400029B2 (en) * 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
IN2013MN02442A (en) 2011-06-28 2015-06-12 Inhibrx Llc
KR102231139B1 (en) * 2011-06-28 2021-03-24 인히브릭스, 인크. Serpin fusion polypeptides and methods of use thereof

Also Published As

Publication number Publication date
MX2013015324A (en) 2014-05-01
AU2012275295B2 (en) 2016-11-10
US20130011399A1 (en) 2013-01-10
US8986688B2 (en) 2015-03-24
EP2726093A2 (en) 2014-05-07
AU2012275295A1 (en) 2014-01-16
WO2013003649A2 (en) 2013-01-03
KR20140068861A (en) 2014-06-09
JP2014528913A (en) 2014-10-30
NZ619035A (en) 2015-07-31
WO2013003649A3 (en) 2013-03-21
AU2017200928A1 (en) 2017-03-02
CN103946388A (en) 2014-07-23
US9914765B2 (en) 2018-03-13
US20150147324A1 (en) 2015-05-28
MX356433B (en) 2018-05-29
EP2726093A4 (en) 2015-08-19
BR112013033801A2 (en) 2017-12-19
RU2639526C2 (en) 2017-12-21
CA2839622A1 (en) 2013-01-03
RU2014102585A (en) 2015-08-10

Similar Documents

Publication Publication Date Title
IN2013MN02442A (en)
IN2013MN02441A (en)
MX2021012047A (en) Serpin fusion polypeptides and methods of use thereof.
BR112019001108A2 (en) uses of extracellular vesicles comprising a fusion protein having fc binding capacity
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX350962B (en) Method for making antibody fc-heterodimeric molecules using electrostatic steering effects.
TN2012000518A1 (en) Serum albumin binding molecules
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
PH12019500596A1 (en) Recombinant binding proteins and their use
EA201691669A1 (en) BINDING SERUM ALBUMIN DOMAINS FIBRONECTIN III TYPE
WO2013184939A3 (en) Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
MX2021006017A (en) Methods and compositions for treatment of disorders with follistatin polypeptides.
MX2016016063A (en) Mic-1 fusion proteins and uses thereof.
WO2012109624A3 (en) Monovalent and multivalent multispecific complexes and uses thereof
WO2013075066A3 (en) Variant serum albumin with improved half -life and other properties
PE20121636A1 (en) IL-2 DERIVED IMMUNOMODULATOR POLYPEPTIDES AND THEIR THERAPEUTIC USE IN CANCER AND CHRONIC INFECTIONS
WO2017053619A8 (en) Glypican-3binding fibronectin based scafflold molecules
MX2015000754A (en) Human btnl3 proteins, nucleic acids, and antibodies and uses thereof.
IN2014DN03213A (en)
WO2014144621A3 (en) Modified fc fusion proteins
NZ724196A (en) Uti fusion proteins
WO2012122378A3 (en) Antibody-like proteins for therapeutic and diagnostic use
MX365560B (en) Cyaa-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses.
MX2015011931A (en) Enhanced expression of picornavirus proteins.
LV15035A (en) Sequences of cdna of recombinant chimeric polypeptide having type two melanocortin receptor (mc2r) and melanocortin receptor accessory protein (mrap) and a use of them for testing active molecules and for therapeutic purposes